Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Randomized, Double-Masked, Placebo-Controlled, Parallel-Group, Multicenter Study Evaluating Teprotumumab (HZN-001) Treatment in Subjects With Active Thyroid Eye Disease

NCT03298867 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT03298867
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03298867 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Randomized, Double-Masked, Placebo-Controlled, Parallel-Group, Multicenter Study Evaluating Teprotumumab (HZN-001) Treatment in Subjects With Active Thyroid Eye Disease
Lead sponsor
Amgen
Phase
Phase 3
Overall status
Completed
Start date
October 4, 2017
Completion date
November 30, 2020
Enrollment
83 (actual)
Sites
14

Conditions

As the registry lists them; a condition with its own page is linked.

graves' orbitopathy, thyroid eye disease